trending Market Intelligence /marketintelligence/en/news-insights/trending/zkleyCAOLX3J6zwXJ_BNbg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

ProQR Therapeutics closes $57.5M shares offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


ProQR Therapeutics closes $57.5M shares offering

ProQR Therapeutics NV closed a public offering of ordinary shares raising about $57.5 million in gross proceeds.

The Leiden, Netherlands-based biopharmaceutical company sold 10,454,545 ordinary shares at $5.5 apiece. This includes 1,363,636 additional shares sold as underwriters fully exercised the overallotment option.

The company previously said it plans to use net proceeds from the offering to fund ongoing research and development activities, for working capital and for other general corporate purposes.

The Dutch biopharmaceutical company develops treatments for genetic disorders.

Citigroup Global Markets and Evercore ISI were joint book-runners for the offering, while Cantor Fitzgerald & Co. and JMP Securities were lead managers. Chardan and Kempen were co-managers.